By focusing on the type 2-high asthma subtype, elucidating the distinct regulatory mechanism of CD36, and establishing a comprehensive in vitro and in vivo validation framework, this study provides systematic evidence for targeting phagocytosis-related mechanisms in asthma therapy. This evidence concerns the gene CD36 and asthma.